Samlyn Capital, LLC Corvus Pharmaceuticals, Inc. Transaction History
Samlyn Capital, LLC
- $5.62 Billion
- Q2 2024
A detailed history of Samlyn Capital, LLC transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Samlyn Capital, LLC holds 6,123,021 shares of CRVS stock, worth $52.7 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
6,123,021
Previous 2,348,363
160.74%
Holding current value
$52.7 Million
Previous $4.18 Million
166.58%
% of portfolio
0.2%
Previous 0.07%
Shares
5 transactions
Others Institutions Holding CRVS
# of Institutions
52Shares Held
28MCall Options Held
22.9KPut Options Held
29.8K-
Orbimed Advisors LLC San Diego, CA6.94MShares$59.8 Million0.3% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.96MShares$51.4 Million0.03% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$28.2 Million2.69% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.65MShares$14.2 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny564KShares$4.86 Million0.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $401M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...